Madrigal Pharmaceuticals Inc

Description

Synta Pharmaceuticals Corp. focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its clinical stage drug candidate in oncology is ganetespib, an Hsp90 inhibitor, which is in Phase II clinical trials to evaluate the combination of ganetespib and paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma, including malignant peripheral nerve sheath tumors. The company's drug candidate in its Hsp90-inhibitor Drug Conjugate program is STA-12-8666, which is in preclinical trials for chemotherapy irinotecan. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.